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Background Cardiac involvement in Anderson–Fabry disease (AFD) can lead to arrhythmia, including ventricular tachycardia
(VT). The literature on radiofrequency ablation (RFA) for the treatment of VT in AFD disease is limited.
...................................................................................................................................................................................................
Case summary We discuss RFA of drug-refractory VT electrical storm in three males with AFD. The first patient (53 years old)
had extensive involvement of the inferolateral left ventricle (LV) demonstrated with cardiac magnetic resonance
imaging (CMRI), with a left ventricular ejection fraction (LVEF) of 35%. Two VT ablation procedures were per-
formed. At the first procedure, the inferobasal endocardial LV was ablated. Furthermore, VT prompted a second
ablation, where epicardial and endocardial sites were ablated. The acute arrhythmia burden was controlled but he
died 4 months later despite appropriate implantable cardioverter-defibrillator therapies for VT. The second patient
(67 years old) had full-thickness inferolateral involvement demonstrated with CMRI and LVEF of 45%. RFA of sev-
eral endocardial left ventricular sites was performed. Over a 3-year follow-up, only brief non-sustained VT was
identified, but he subsequently died of cardiac failure. Our third patient (69 years old), had an LVEF of 35%. He had
RFA of endocardial left ventricular apical disease, but died 3 weeks later of cardiac failure.
...................................................................................................................................................................................................
Discussion RFA of drug-refractory VT in AFD is feasible using standard electrophysiological mapping and ablation techniques,
although the added clinical benefit is of questionable value. VT storm in the context of AFD may be a marker of
end-stage disease.
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Learning points
• Ventricular tachycardia (VT) storm in Anderson–Fabry disease (AFD) is due to re-entry around areas of fibrosis, and traditional principles
for VT ablation can be used to acutely terminate the arrhythmia.
• VT resistant to medical therapy in patients with AFD is likely to represent end-stage disease when severe left ventricular systolic dysfunc-
tion and extensive late gadolinium enhancement are present.
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Introduction
Anderson–Fabry disease (AFD) is a rare, X-linked storage disorder
caused by deficiency of the enzyme a-galactosidase A resulting in ac-
cumulation of globotriaosylceramide in organs including the heart,
kidneys, and nervous system.1 Lipid deposition, inflammation and fi-
brosis within the myocardial interstitium causes infiltrative hyper-
trophic cardiomyopathy and cardiac conduction tissue disease.2 The
commonest arrhythmias in AFD are atrial fibrillation3,4 and ventricu-
lar tachycardia (VT).5–7 Here, we review the literature and report
our experience of radiofrequency ablation (RFA) in three patients




May 2013 Initial presentation with presyncope. Monitoring:
non-sustained ventricular tachycardia (NSVT).
Cardiac magnetic resonance imaging (CMRI):
left ventricular hypertrophy, left ventricular
ejection fraction (LVEF) 61%.
July 2013 Anderson–Fabry disease (AFD) confirmed (serum
alpha-galactosidase level 0.2 mmol/L/h; I117S
mutation later identified). Enzyme replacement
therapy started.
October 2013 Elective dual chamber implantable cardioverter-
defibrillator (ICD) implantation.
September 2014 Echocardiography: LVEF 51%.
December 2015 Echocardiography: LVEF 35%.
May 2016 Admission following ICD shock delivery for sus-
tained monomorphic ventricular tachycardia
(SMVT). ICD reprogrammed.
May 2016 Further ICD therapy. SMVT and hypotension on
admission. In-hospital cardiac arrest requiring
cardiopulmonary resuscitation (CPR) with re-
turn of spontaneous circulation. Incessant ven-
tricular tachycardia (VT) despite
antiarrhythmics, overdrive pacing and anti-
tachycardia pacing (ATP). Emergency radiofre-
quency VT ablation.
May 2016 Recurrent SMVT resistant to medical therapy.
Second VT ablation. Polymorphic VT following
ablation, requiring CPR and re-intubation.
May–July 2016 Recovery complicated by ventilator-associated
pneumonia, prolonged mechanical ventilation
(21 days) and a stroke. Successfully rehabilitated
and discharged 7 weeks after the second
ablation.






Admission with palpitations. SMVT on monitoring,
responding to lignocaine. Beta-blocker dose
increased.
September 2016 Palpitations at home. Three ICD shocks.
Subsequent pulseless electrical activity arrest,
CPR unsuccessful.
Case 2
May 2015 Initial presentation with syncope: SMVT, requiring
direct current cardioversion. Hypertrophic car-
diomyopathy diagnosed on CMRI. LVEF 59%.
Dual chamber ICD implantation. AFD con-
firmed (serum alpha-galactosidase level 0.3
mmol/L/h; P.N215S mutation).
June 2015 Enzyme replacement therapy started.
May 2016 Admission with palpitations and presyncope.
Recurrent SMVT observed. Echocardiography:
LVEF 45%.
May 2016 Inpatient VT ablation. Discharged 4 days later.
July–August
2018
Admission with heart failure and symptomatic
atrial fibrillation (AF). Good response to diu-
retics. Acutely successful electrical cardiover-
sion for AF.
June 2018 Two episodes of NSVT (each lasting 6–8 s)
detected via ICD.
July 2019 Treated for refractory heart failure with palliative





December 2007 Abnormal preoperative electrocardiogram.
Hypertrophic cardiomyopathy diagnosed on
CMRI. LVEF 61%.
February 2012 AFD confirmed (serum alpha-galactosidase level
0.45 mmol/L/h; N215S mutation identified).
Enzyme replacement therapy started.
September 2016 Admission with SMVT leading to dual-chamber
ICD implantation.
July 2018 Echocardiography: LVEF 35%.
November 2018 Admission following ICD shock delivery. Device
interrogation: SMVT.
December 2018 Emergency external direct current cardioversion
due to SMVT with hypotension.
December 2018 Acute kidney injury and acute liver injury second-
ary to VT-associated hypotension.
December 2018 Daily episodes of SMVT, resistant to antiarrhyth-
mic therapy.
December 2018 Radiofrequency ablation of VT.
December 2018 Episodes of SMVT responding to ATP. Escalating
doses of furosemide and dobutamine.
December 2018 Worsening heart failure with fluid overload and
renal dysfunction. Decision to palliate: ICD
therapies deactivated, medical therapy discon-











































































































































































































































































This 53-year-old man with a background of well-controlled asthma
presented with exertional presyncope. Non-sustained VT (NSVT)
was observed. Cardiac magnetic resonance imaging (CMRI) showed
left ventricular hypertrophy (LVH) with a septal thickness of 24mm,
thinning of the basal inferolateral left ventricular wall, a left ventricular
ejection fraction (LVEF) of 61%, and extensive mid-wall late gadolin-
ium enhancement (LGE) of the mid and distal inferolateral left ven-
tricle (LV) (Figure 1). Coronary angiography excluded obstructive
coronary artery disease (CAD). A diagnosis of AFD was confirmed in
July 2013 (I117S mutation). Enzyme replacement therapy (ERT) was
commenced with intravenous (IV) agalsidase alfa (Replagal), and
amiodarone 200mg daily. A dual-chamber implantable cardioverter-
defibrillator (ICD) was implanted. Over the next 18months, LVEF
declined to 35% despite angiotensin-converting enzyme inhibitor and
beta blocker therapy. Pacing records showed a ventricular pacing
burden of 1–2% during this time.
Three years later, he had an episode of sustained monomorphic
VT (SMVT), converted to sinus rhythm (Figure 2A) with a single ICD
shock. He received another shock from his ICD 10 days later. His 12-
lead electrocardiogram (ECG) during VT showed a rate of 175
b.p.m., a right bundle branch block (RBBB) pattern, and left-superior
axis (Figure 3A). Despite an initial blood pressure (BP) of 65/
37mmHg, he lost cardiac output and required 20min of cardiopul-
monary resuscitation (CPR), with 15 internal and external shocks be-
fore return of spontaneous circulation. Despite treatment with IV
amiodarone, lignocaine, carvedilol, heavy sedation with intubation
and attempts at overdrive pacing, his VT was incessant with persist-
ent hypotension and we proceeded to an emergency electrophysio-
logical study (EPS).
The VT terminated during catheter manipulation and was subse-
quently intermittent. Endocardial mapping of the LV was performed
using a decapolar mapping catheter (Inquiry AFocus, EnSite
VelocityTM, Abbott). Mapping of the left ventricular substrate, activa-
tion, late potentials, and pace-mapping revealed areas of interest for
ablation at the inferobasal left ventricular endocardium. RFA was per-
formed from the site of earliest activation of VT in the LV forming a
line of block from the scar to the mitral value annulus, incorporating
the areas of interest (Flexability ablation catheter, 40-W power).
Subsequent VT stimulation with three extras was negative. IV amio-
darone was continued, and lignocaine stopped.
Three days later, he had recurrent SMVT of same morphology, re-
sistant to re-initiation of lignocaine. A second EPS was performed,
this time endocardially and epicardially (110mm 16G Tuohy needle).
Initially, we observed a paced rhythm with frequent monomorphic
(right bundle, left superior axis) premature ventricular complexes
(PVCs), of similar morphology to the initial VT. Endocardial and epi-
cardial mapping of the PVCs was performed [EnSite VelocityTM
Cardiac Mapping System (Abbott) using AFocusTM catheter].
Extensive epicardial scar was noted. The origin of the PVCs corre-
sponded with an island of healthier tissue within scar on the basal epi-
cardial inferoseptal LV. This was targeted with RFA, with abolition of
the PVCs. Further VT (right bundle, left superior axis) was induced
with right ventricular pacing, but due to haemodynamic instability it
Figure 1 Cardiac magnetic resonance imaging in the three patients, prior to implantable cardioverter-defibrillator implantation.
RFA of VT in AFD 3
Figure 2 Twelve-lead electrocardiogram during sinus rhythm. Case 1 (A); Case 2 (B); and Case 3 (C).
4 M.T. Mills et al.
Figure 3 Twelve-lead electrocardiogram during VT. Case 1 (A): immediately before ventricular tachycardia ablation. Case 2 (B): on admission, 3
days prior to ventricular tachycardia ablation. Case 3 (C): 3 days after admission, shortly before external direct current cardioversion.














































































































































































was not possible to map. Good pacemapping from an area of late
potentials at the epicardial apical inferolateral sites was targeted for
ablation. Pace mapping was also performed in the endocardial LV.
‘Good’ sites (11/12 match) were noted at the inferolateral apical LV
and ablated. The procedure concluded once no further sites for
ablation were identified. No further VT induction was attempted
due to the very high risk of precipitating further haemodynamic
decompensation.
Shortly after the procedure, he had polymorphic VT requiring ICD
therapies, external defibrillation, CPR, dopamine and adrenaline infu-
sions, and intra-aortic balloon pump insertion. Resuscitation was
acutely successful and he was transferred to the intensive therapy
unit.
Recovery was complicated by a ventilator-associated pneumonia,
prolonged mechanical ventilation (21 days) and a stroke. He was dis-
charged 7 weeks after the ablation, requiring a stick to walk. He
remained on oral amiodarone. Over the next 2 months, he had VT
treated with anti-tachycardia pacing (ATP) and a second episode
requiring a short admission for IV lignocaine.
Four months after the ablation procedures, he received three ICD
shocks for SMVT, followed by pulseless electrical activity. CPR was
unsuccessful.
Case 2
This 67-year-old man presented with presyncope on exercise due to
VT, requiring direct current cardioversion (DCCV). CMRI at presen-
tation demonstrated LVH (maximal septal thickness 22mm), regional
thinning and akinesia, LVEF of 59%, and full thickness LGE affecting
the basal and mid-chamber inferior, inferolateral and anterolateral
segments (Figure 1). A diagnosis of AFDwas confirmed (P.N215Smu-
tation), and Replagal started. He had no other past medical history of
note, and coronary angiography excluded CAD. A dual chamber ICD
was implanted in 2015. Device interrogation found a right ventricular
(RV) pacing burden of 2–9%.
A year later, he represented with presyncope. The rhythm was
SMVT at a rate of 161 b.p.m. (below the device programmed treat-
ment zone), with RBBB morphology, and superior axis (Figure 3B). BP
was 97/51mmHg. Despite treatment with IV amiodarone, the rate
increased and he was cardioverted via his ICD (Figure 2B). His biso-
prolol dose was increased and oral amiodarone started.
Echocardiography showed an LVEF of 45%. Over the next 3 days, re-
current NSVT without haemodynamic compromise was treated with
IV amiodarone, lignocaine, and ATP.
EPS was performed 4 days after admission. Mapping of the LV was
performed in sinus rhythm (EnSite Velocity mapping system, AFocus
catheter, Abbott). Late potentials were seen in mid-inferolateral,
mid-septal, and anteroapical sites. Scar mapping revealed large areas
of dense scar in the inferolateral LV and the basal to mid-septal and
anteroapical regions. Programmed electrical stimulation in the RV
apex and various LV sites (up to three ventricular extrastimuli) did
not induce VT. Pace-mapping was best at the mid-apical inferolateral
regions. Ablation of the inferolateral, basal to mid-septal and ante-
roapical LV was undertaken. Shortly after the procedure, he had two
episodes of NSVT, but no further episodes whilst an inpatient. He
was discharged 4 days later with oral amiodarone and metoprolol.
Amiodarone was discontinued in March 2017.
He remained stable for 2 years. Device interrogation between
September 2016 and August 2019 demonstrated two episodes of
NSVT, each lasting 6–8 s. In July 2018, he was hospitalized for 7 weeks
due to decompensated heart failure in atrial fibrillation, responding to
diuretics and DCCV. His LVEF had deteriorated to 38% and heart
failure continued to progress despite medical treatment. A decision
was made to treat this palliatively. He died in September 2019.
Case 3
This 69-year-old man with hypertension had an abnormal routine
preoperative ECG (Figure 2C) in 2007 and was diagnosed with hyper-
trophic cardiomyopathy. CMRI showed asymmetrical LVH (24mm)
and LVEF of 61%. A diagnosis of AFD (N215S mutation) was con-
firmed in 2012, when ERT was started. An ICD was implanted after
an episode of SMVT in 2016. Repeated CMRI revealed deterioration
in left ventricular systolic function (LVEF 48%), with diffuse LGE in
the basal to mid inferolateral LV ‘LV/RV hinge points’ and the left ven-
tricular anteroseptum and apex (Figure 1). Coronary angiography
excluded significant CAD. Echocardiography in July 2018 showed fur-
ther deterioration in left ventricular systolic function (LVEF 35%),
treated with standard heart failure therapy.
He presented in November 2018 after receiving shocks from his
ICD. Device interrogation confirmed two episodes of SMVT, failing
to respond to ATP, finally treated with shocks. RV pacing burden had
been 0–8%, although the basal pacing rate was then increased from
50 to 80 b.p.m., and he was commenced on IV amiodarone. Three
days later, an episode of SMVT (Figure 3C) with hypotension
prompted emergency external DCCV. Over the next 9 days, he had
daily episodes of SMVT, without haemodynamic compromise,
responding to ATP. He was treated with IV lignocaine to control the
SMVT and milrinone to treat persistent cardiogenic shock. Despite
this, he had daily episodes of SMVT requiring ATP. He developed
acute kidney and liver injuries, likely due to hypoperfusion during epi-
sodes of VT, although amiodarone was discontinued due to possible
hepatotoxicity.
Three weeks into the admission, EPS was performed. VT induction
was not attempted due to haemodynamic instability. Transseptal
puncture and left ventricular mapping was performed during RV pac-
ing, demonstrating extensive apical left ventricular scar (Figure 4).
Pacemaps similar to the clinical VT (Figure 5A), and delayed potentials
were recorded at the left ventricular apex (Figure 5B). Isolation of the
left ventricular apex with loss of local pace capture was achieved with
local impedance-guided RFA applications.
Following EPS, lignocaine and milrinone were stopped. Further
episodes of SMVT responding to ATP were observed over the next
3 days, but thereafter no VT was seen. Despite treatment with IV fur-
osemide and dobutamine, he remained in cardiogenic shock. A joint
decision was made to deactivate his ICD, discontinue medical ther-
apy, and palliate. He died 11 days later.
Review of literature
Whilst multi-organ involvement is common in AFD, mortality is pri-
marily caused by cardiac disease. A systematic review by Baig et al.8
identified 13 studies on ventricular arrhythmias and sudden cardiac
death (SCD) in AFD. In this review, 75% of deaths were due to a














































































































































































cardiovascular condition and 62% of all deaths were reported as
SCD events. The average prevalence of VT was reported as 15.3%.
Factors associated with SCD included increasing age, LGE on CMRI,
and NSVT.
We identified four case reports pertaining to the description of
RFA of VT in AFD. Higashi et al.9 described the case of a 67-year-old
man with an LVEF of 35% and a left lateral ventricle wall perfusion de-
fect, presenting with VT storm resistant to anti-arrhythmic therapy.
Epicardial activation mapping demonstrated a figure-of-eight re-en-
trant circuit on the lateral left ventricular wall. RFA to this region ter-
minated the VT. Over a 24-month follow-up, recurrence of a non-
ablated VT was observed, and the number of ICD shocks for VT
decreased. In another study, Nakano et al.10 report on a 51-year-old
man with an LVEF of 68%, presenting with SMVT. CMRI demon-
strated high T2 signal in the basal epicardium and antero-septal endo-
cardium. The patient underwent RFA of the left ventricular anterior-
apical wall, with recurrence of the VT a few days after. A second abla-
tion was performed but did not completely eradicate the VT. The pa-
tient was continued on long-term amiodarone and remained alive at
2 years, with no documented VT recurrence. A report by Ellis et al.11
described a 49-year-old man with AFD, LVEF 25–30%, permanent
atrial fibrillation and complete heart block (with cardiac resynchroni-
zation therapy ICD), presenting with VT storm resistant to anti-
arrhythmic therapy. EPS demonstrated a posterolateral site of origin
near the mitral annulus, and RFA was performed at this site, with no
VT subsequently inducible. Follow-up was limited to 3 months, with-
out VT recurrence. In an abstract by Oder et al.,12 the authors
describe the use of RFA in three patients with Fabry disease, two of
whom experienced further VT episodes following the procedure and
died due to end-stage heart failure.
With regards to guidance on ICD implantation in AFD, evidence is
sparse. In a retrospective analysis of patients with AFD,13 several clin-
ical factors were associated with ICD implantation, including increas-
ing age, greater left ventricular mass, greater scar tissue, and larger
atrial size. Importantly, only 28% of AFD patients with an ICD in this
study had a Class 1 indication for implantation, highlighting the need
for AFD-specific research and guidelines.
Discussion
Imaging
CMRI in our cohort showed extensive LGE, which was predominant-
ly inferolateral mid-wall, patchy, extending from base to apex. Whilst
the morphology of the VT on the 12-lead ECGs was variable, it did
correspond with observed areas of LGE. In Case 1, an inferior basal
septum origin, in Case 2, a lateral mid-chamber origin, and in Case 3,
an apical wall origin.
All our patients had relatively stable slow SMVT (Figure 2) with
rates between 150 and 180min-1 and in one case the QRS had
delayed intrinsicoid deflection, suggestive of epicardial breakout.
Ablation strategy
In our series, the mechanism of VT was re-entry around areas of fi-
brosis, and traditional principles for VT ablation were deemed appro-
priate. The substrate is transmural and the critical isthmus may be
found endocardially but can be present anywhere within the myocar-
dium. Despite extensive myocardial fibrosis in our cases, left ventricu-
lar walls remained hypertrophied. Accordingly, ablated areas were
frequently in thickened myocardium, likely to hinder lesion transmur-
ality. These factors suggest that a combined endocardial/epicardial
approach may be helpful, although an endocardial-only approach was
used in our most successful case who survived beyond three years.
In two of our cases, VTwas not inducible at the end of the proced-
ure (in the third, VT induction was not attempted due to haemo-
dynamic instability). Therefore, inducibility does not appear to be a
reliable marker of subsequent VT risk, so comprehensive treatment
may involve complete substrate modification where possible.
Left ventricular function
Our experience suggests that VT resistant to medical therapy in
patients with AFD is likely to represent end-stage disease when
severe left ventricular systolic dysfunction (LVSD) and extensive
LGE are present. At the start of our case series, all patients had
preserved LVEF, which later deteriorated after ICD implantation.
Two had severe LVSD at the time of ablation; Case 1 who died
4 months following VT ablation, and Case 3 who died 2 weeks
after. In contrast, Case 2 had moderate LVSD at the time of abla-
tion, and survived more than 3 years following the procedure, al-
though it must be acknowledged that prior to EPS, the patient
had been stabilized on amiodarone which was continued for 10
months following the procedure. In our experience of over 175
patients with cardiac AFD, it appears that VT electrical storm in
AFD patients is a marker of end-stage disease.
Figure 4 Bipolar voltage map and ablation lesions from ventricu-
lar tachycardia ablation (Case 3). The low voltage areas observed
using conventional voltage criteria corresponded with late
Gadolinium-enhanced areas seen with cardiac magnetic resonance
(Figure 1, Case 3). There was mid-distal anteroseptal, apical, and
posterolateral scar. Substrate-based ablation was performed guided
by late potentials and pacemaps. Ventricular tachycardia was not in-
ducible pre- or post-ablation. AP, antero-posterior; Bi, bipolar tissue
voltage; Imp, impedance drop observed during radiofrequency abla-
tion; LAO, left anterior oblique; LPO, left posterior oblique view.
RFA of VT in AFD 7
Figure 5 Twelve-lead electrocardiogram (A) recorded during left ventricular pacing from an antero-apical site, demonstrating reasonable match
with the clinical ventricular tachycardia (Figure 3C). Intracardiac electrograms (B) recorded during right ventricular pacing with the Pentarray (PENT)
roving catheter (BiosenseWebster) positioned in the left ventricle at the same apical site as the pace map displayed above. Delayed post-QRS poten-
tials are seen in this area (arrows). CS, coronary sinus catheter.

























































































































AFD can present with VT consistent with a re-entry mechanism. In
our series of three patients with VT storm refractory to medical ther-
apy, extensive infiltration and/or scar was demonstrated by LGE.
Endocardial ± epicardial mapping demonstrated the arrhythmic sub-
strate. However, RFA did not result in a significant prognostic benefit
in two out of the three patients. In patients with AFD, VT storm is
therefore likely a sign of end-stage disease.
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